Trending
- 1 ASTELLAS PHARMA INC.: FDA Accepts for Priority Review the New Drug Application for mirabegron for Oral Suspension and Supplemental New Drug Application for Myrbetriq® (mirabegron) Tablets in Pediatric Patients
- 2 FUNCTIONAL NEUROMODULATION: Announces Breakthrough Device Designation from the U.S. FDA for Deep Brain Stimulation for Alzheimer's Disease
Newsletter
Get the latest business news and updates - delivered right to your inbox
By signing up you agree to receive email newsletters or alerts from FDA Reporter. You can unsubscribe at any time.